Financing led by Canaan and New Leaf Venture Partners, and includes funds managed by abrdn Inc., Correlation Ventures, and Mayo Clinic Ventures DEDHAM, Mass. — April 30, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. […]
News and EventsNews and Events
Qlaris Bio’s Novel IOP-Lowering Product, QLS-111, Is Dosed In Phase II Trials
A first-in-class product, QLS‑111 is designed to lower intraocular pressure (IOP) beyond currently achievable levels in patients with glaucoma by targeting episcleral venous pressure (EVP) DEDHAM, Mass. — April 2, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate […]
An Interview With Dr. Shan Lin – Unmet Needs in Glaucoma & New Treatments On The Horizon
Please click below for an interview with Dr. Shan Lin, co-research director of the Glaucoma Center of San Francisco and a member of the Scientific Advisory Board of Qlaris Bio – Interviewed by Carey Powers of Powers & Company at the Glaucoma 360 New Horizons Forum 2024. https://vimeo.com/929695079
Qlaris Bio Named 2022 Scrip Awards Finalist for Biotech Company of the Year
Annual awards program recognizes innovations and achievements in global biopharma Wellesley, Mass., September 28, 2022 – Qlaris Bio, Inc, a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today it has been named a finalist in the WuXi AppTec’s Biotech Company of the Year category of the 2022 Scrip Awards. Qlaris has seen […]
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101 Findings from First-in-Human Study Support Continued Clinical Development of Investigational IOP-lowering Therapy; New Trials Planned as Complementary Glaucoma Treatment and in Rare Pediatric Indication Wellesley, Mass., May 18, 2022 – Qlaris Bio, Inc. (the “Company” or “Qlaris”), […]
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational TherapyDesigned to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma -Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND) Application- Wellesley, Mass., April 15, 2021 — Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic […]